RelatedCAS#:1204313-51-8(HCl) 610798-31-7(freebase) 

Synonym:BPI2009;BPI2009;BPI-2009;Icotinib;Brandname:Conmana.

IUPAC/ChemicalName:N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-aminehydrochloride

InChiKey:PNNGXMJMUUJHAV-UHFFFAOYSA-N

InChiCode:InChI=1S/C22H21N3O4.ClH/c1-2-16-4-3-5-17(12-16)25-22-18-13-20-21(14-19(18)23-15-24-22)29-11-9-27-7-6-26-8-10-28-20;/h1,3-5,12-15H,6-11H2,(H,23,24,25);1H

SMILESCode:C#CC1=CC(NC2=C3C=C(OCCOCCOCCO4)C4=CC3=NC=N2)=CC=C1.[H]Cl

TechnicalData

AdditionalInformation

IcotinibwasapprovedinChinain2011.

References

1:ChenX,ZhuQ,LiuY,LiuP,YinY,GuoR,LuK,GuY,LiuL,WangJ,WangZ,RøeOD,ShuY,ZhuL.Icotinibisanactivetreatmentofnon-small-celllungcancer:aretrospectivestudy.PLoSOne.2014May16;9(5):e95897.doi:10.1371/journal.pone.0095897.eCollection2014.PubMedPMID:24836053;PubMedCentralPMCID:PMC4023939.

2:PanH,LiuR,LiS,FangH,WangZ,HuangS,ZhouJ.EffectsofIcotinibonAdvancedNon-SmallCellLungCancerwithDifferentEGFRPhenotypes.CellBiochemBiophys.2014Apr29.[Epubaheadofprint]PubMedPMID:24777808.

3:GuanYS,HeQ,LiM.Icotinib:activityandclinicalapplicationinChinesepatientswithlungcancer.ExpertOpinPharmacother.2014Apr;15(5):717-28.doi:10.1517/14656566.2014.890183.Epub2014Mar4.PubMedPMID:24588695.

4:LiangW,WuX,FangW,ZhaoY,YangY,HuZ,XueC,ZhangJ,ZhangJ,MaY,ZhouT,YanY,HouX,QinT,DinglinX,TianY,HuangP,HuangY,ZhaoH,ZhangL.Networkmeta-analysisoferlotinib,gefitinib,afatinibandicotinibinpatientswithadvancednon-small-celllungcancerharboringEGFRmutations.PLoSOne.2014Feb12;9(2):e85245.doi:10.1371/journal.pone.0085245.eCollection2014.PubMedPMID:24533047;PubMedCentralPMCID:PMC3922700.

5:LiuD,JiangJ,ZhangL,TanF,WangY,ZhangD,HuP.ClinicalpharmacokineticsofIcotinib,ananti-cancerdrug:evaluationofdoseproportionality,foodeffect,andtolerABIlityinhealthysubjects.CancerChemotherPharmacol.2014Apr;73(4):721-7.doi:10.1007/s00280-014-2398-8.Epub2014Feb1.PubMedPMID:24488324.

6:ShaoL,ZhangB,HeC,LinB,SongZ,LouG,YuX,ZhangY.EfficacyandsafetyoficotinibinChinesepatientswithadvancednon-smallcelllungcancerafterfailureofchemotherapy.ChinMedJ(Engl).2014;127(2):266-71.PubMedPMID:24438614.

7:GuanY,ZhaoH,MengJ,YanX,JiaoS.Dramaticresponsetohigh-doseicotinibinalungadenocarcinomapatientaftererlotinibfailure.LungCancer.2014Feb;83(2):305-7.doi:10.1016/j.lungcan.2013.12.002.Epub2013Dec12.PubMedPMID:24370197.

8:ZhaoQ,WangY,TangY,PengL.Icotinibcombinedwithrapamycininarenaltransplantrecipientwithepidermalgrowthfactorreceptor-mutatednon-smallcelllungcancer:Acasereport.OncolLett.2014Jan;7(1):171-176.Epub2013Nov5.PubMedPMID:24348843;PubMedCentralPMCID:PMC3861587.

9:SunX,ZhengY.Retreatmentwithicotinibinapatientwithmetastaticlungadenocarcinoma.Tumori.2013May-Jun;99(3):e124-6.doi:10.1700/1334.14820.PubMedPMID:24158081.

10:ShiY,ZhangL,LiuX,ZhouC,ZhangL,ZhangS,WangD,LiQ,QinS,HuC,ZhangY,ChenJ,ChengY,FengJ,ZhangH,SongY,WuYL,XuN,ZhouJ,LuoR,BaiC,JinY,LiuW,WeiZ,TanF,WangY,DingL,DaiH,JiaoS,WangJ,LiangL,ZhangW,SunY.Icotinibversusgefitinibinpreviouslytreatedadvancednon-small-celllungcancer(ICOGEN):arandomised,double-blindphase3non-inferioritytrial.LancetOncol.2013Sep;14(10):953-61.doi:10.1016/S1470-2045(13)70355-3.Epub2013Aug13.PubMedPMID:23948351.

11:CamidgeDR.Icotinib:kick-startingtheChineseanticancerdrugindustry.LancetOncol.2013Sep;14(10):913-4.doi:10.1016/S1470-2045(13)70385-1.Epub2013Aug13.PubMedPMID:23948350.

12:YangX,ZhangH,QinN,LiX,NongJ,LvJ,WuY,ZhangQ,ZhangS.[Clinicalobservationoficotinibhydrochlorideinfirst-linetherapyforpulmonaryadenocarcinoma].ZhongguoFeiAiZaZhi.2013Jul;16(7):364-8.doi:10.3779/j.issn.1009-3419.2013.07.06.Chinese.PubMedPMID:23866667.

13:NongJ,QinN,WangJ,YangX,ZhangH,WuY,LvJ,ZhangQ,ZhangS.[Clinicaleffectsforpatientswithrecurrentadvancednon-smallcelllungcancertreatedwithicotinibhydrochloride].ZhongguoFeiAiZaZhi.2013May;16(5):240-5.doi:10.3779/j.issn.1009-3419.2013.05.05.Chinese.PubMedPMID:23676980.

14:LvC,MaY,FengQ,FangF,BaiH,ZhaoB,YanS,WuN,ZhengQ,LiS,ChenJ,WangJ,FengY,WangY,PeiY,FangJ,YangY.Apilotstudy:sequentialgemcitabine/cisplatinandicotinibasinductiontherapyforstageIIBtoIIIAnon-small-celllungadenocarcinoma.WorldJSurgOncol.2013Apr26;11:96.doi:10.1186/1477-7819-11-96.PubMedPMID:23621919;PubMedCentralPMCID:PMC3643858.

15:GaoZ,ChenW,ZhangX,CaiP,FangX,XuQ,SunY,GuY.Icotinib,apotentandspecificEGFRtyrosinekinaseinhibitor,inhibitsgrowthofsquamouscellcarcinomacelllineA431throughnegativelyregulatingAKTsignaling.BiomedPharmacother.2013Jun;67(5):351-6.doi:10.1016/j.biopha.2013.03.012.Epub2013Apr2.PubMedPMID:23602321.

16:MuX,ZhangY,QuX,HouK,KangJ,HuX,LiuY.UbiquitinligaseCbl-bisinvolvedinicotinib(BPI-2009H)-inducedapoptosisandG1phasearrestofEGFRmutation-positivenon-small-celllungcancer.BiomedResInt.2013;2013:726375.doi:10.1155/2013/726375.Epub2013Mar19.PubMedPMID:23586056;PubMedCentralPMCID:PMC3615596.

17:SongZ,YuX,CaiJ,ShaoL,LinB,HeC,ZhangB,ZhangY.[Efficacyoficotinibforadvancednon-smallcelllungcancerpatientswithEGFRstatusidentified].ZhongguoFeiAiZaZhi.2013Mar;16(3):138-43.doi:10.3779/j.issn.1009-3419.2013.03.04.Chinese.PubMedPMID:23514942.

18:GuA,ShiC,XiongL,ChuT,PeiJ,HanB.Efficacyandsafetyevaluationoficotinibinpatientswithadvancednon-smallcelllungcancer.ChinJCancerRes.2013Feb;25(1):90-4.doi:10.3978/j.issn.1000-9604.2012.12.07.PubMedPMID:23372346;PubMedCentralPMCID:PMC3555305.

19:ZhaoQ,WangYN,WangB.Sparedpre-irrADIatedareainpustularlesionsinducedbyicotinibshowingdecreasedexpressionsofCD1a+langerhanscellsandFGFR2.JpnJClinOncol.2013Feb;43(2):200-4.doi:10.1093/jjco/hys209.Epub2012Dec21.PubMedPMID:23264674.

20:ZhengY,FangW,XuN.Hand-footsyndromeinapatientwithmetastaticlungadenocarcinomainducedbyhigh-doseicotinib:Acasereportandreviewoftheliterature.OncolLett.2012Dec;4(6):1341-1343.Epub2012Sep10.PubMedPMID:23205134;PubMedCentralPMCID:PMC3506748.